Teva Pharmaceutical Industries Ltd Adr (TEVA)

Sep 08, 2026

Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research

Sep 08, 2026

Sep 07, 2026

Teva plans senior notes offering to refinance existing debt By Investing.com - Investing.com Canada

Sep 07, 2026

Sep 04, 2026

TEVA Stock Quote Price and Forecast - cnn.com

Sep 04, 2026

Sep 04, 2026

TEVA Stock Price, Quote & Chart - ChartMill

Sep 04, 2026

Sep 01, 2026

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - TradingView

Sep 01, 2026

Aug 29, 2026

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - Sahm

Aug 29, 2026

Aug 27, 2026

Teva Pharma Industries Ltd ADR (TEVA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 27, 2026

Aug 25, 2026

Teva stock hits 52-week high at 37.84 USD By Investing.com - Investing.com South Africa

Aug 25, 2026

Aug 25, 2026

Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA - Sahm

Aug 25, 2026

Aug 21, 2026

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm

Aug 21, 2026

Aug 19, 2026

Teva receives FDA priority review for Tourette drug - grafa.com

Aug 19, 2026

Aug 19, 2026

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Aug 19, 2026

Aug 18, 2026

Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria

Aug 18, 2026

Aug 17, 2026

TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan

Aug 17, 2026

Aug 13, 2026

Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria

Aug 13, 2026

Aug 13, 2026

Teva stock hits 52-week high at 37.35 USD - Investing.com

Aug 13, 2026

Aug 11, 2026

Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada

Aug 11, 2026

Aug 08, 2026

Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm

Aug 08, 2026

Aug 05, 2026

Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm

Aug 05, 2026

Aug 01, 2026

Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar

Aug 01, 2026

Jul 31, 2026

July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm

Jul 31, 2026

Jul 30, 2026

Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm

Jul 30, 2026

Jul 29, 2026

Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket - Investing.com

Jul 29, 2026

Jul 28, 2026

Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media

Jul 28, 2026

Jul 27, 2026

Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma

Jul 27, 2026

Jul 25, 2026

Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView

Jul 25, 2026

Jul 25, 2026

Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm

Jul 25, 2026

Jul 24, 2026

Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK

Jul 24, 2026

Jul 24, 2026

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 24, 2026

Jul 17, 2026

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm

Jul 17, 2026

Jul 14, 2026

MINT,TEVA Volatility & Greeks - Finviz

Jul 14, 2026

Jul 14, 2026

Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm

Jul 14, 2026

Jul 11, 2026

Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm

Jul 11, 2026

Jul 10, 2026

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm

Jul 10, 2026

Jul 09, 2026

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm

Jul 09, 2026

Jul 08, 2026

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm

Jul 08, 2026

Jul 07, 2026

Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment - Investing.com

Jul 07, 2026

Jul 06, 2026

Teva stock leans on its generic drug base. - Ad-hoc-news.de

Jul 06, 2026

Jul 05, 2026

883035 Forecast — Price Target — Prediction for 2027 - TradingView

Jul 05, 2026

Jul 03, 2026

TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz

Jul 03, 2026

Jul 02, 2026

How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm

Jul 02, 2026

Jul 01, 2026

India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research

Jul 01, 2026

Jun 28, 2026

Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView

Jun 28, 2026

Jun 28, 2026

Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView

Jun 28, 2026

Jun 26, 2026

TEV Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 26, 2026

TEVA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 26, 2026

TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026